Chugai Announces Positive Phase 3 Results for Oral GLP-1 Orforglipron in Weight Maintenance Trial
I'm PortAI, I can summarize articles.
Chugai Pharmaceutical Co., Ltd. announced positive Phase 3 results for orforglipron, an oral GLP-1 receptor agonist, in the ATTAIN-MAINTAIN trial. The trial showed successful weight maintenance at 52 weeks compared to placebo after initial weight loss with injectable GLP-1 therapies. Eli Lilly has submitted orforglipron to the FDA for obesity treatment.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments